|
|||||
|
|
Serum Insulin-Like Growth Factor-1 Binding Proteins 1 and 2 and Mortality in Older Adults: The Health, Aging, and Body Composition Study |
|
| Authors: | Donglei Hu PhD Ludmila Pawlikowska PhD Alka Kanaya MD Wen-Chi Hsueh PhD Lisa Colbert PhD Anne B. Newman MD Suzanne Satterfield MD DrPH Clifford Rosen MD Steven R. Cummings MD Tamara B. Harris MD Elad Ziv MD for the Health Aging Body Composition Study |
| Affiliation: | From the Department of Medicine,;Institute for Human Genetics,;Department of Anesthesia,;Department of Epidemiology and Biostatistics,;Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California;;Department of Kinesiology, University of Wisconsin, Madison, Wisconsin;;Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania;;Department of Preventive Medicine, University of Tennessee, Memphis, Tennessee;;Jackson Laboratory and St. Joseph Hospital, Bangor, Maine;;California Pacific Medical Center Research Institute, San Francisco, California;and;Laboratory of Epidemiology, Demography and Biometry, National Institute on Aging, National Institutes of Health, Bethesda, Maryland. |
| Abstract: | OBJECTIVE: To evaluate the relationship between serum insulin-like growth factor 1 (IGF-1), IGF-1 binding protein 1 (IGFBP-1), and IGF-1 binding protein 2 (IGFBP-2) and fasting insulin, fasting glucose, adiposity, and mortality in older adults. DESIGN: A prospective cohort study with mean follow-up of 6.2 years. SETTING: Participants were recruited and followed at two centers affiliated with academic medical institutions. PARTICIPANTS: Six hundred twenty-five men and women aged 70 and older and in good health at the time of enrollment. MEASUREMENTS: Serum IGF-1, IGFBP-1, and IGFBP-2; fasting serum insulin; fasting serum glucose; visceral fat; and total percent fat. RESULTS: Higher IGFBP-1 and higher IGFBP-2 were significantly associated with lower fasting insulin, lower fasting glucose, and lower adiposity, but higher IGFBP-1 and IGFBP-2 were associated with greater mortality. In multivariate adjusted models, the hazard ratio for all-cause mortality was 1.48 (95% confidence interval (CI)=1.14–1.92) per standard deviation (SD) increase in IGFBP-2 and 1.34 (95% CI=1.01–1.76) per SD increase in IGFBP-1. No association was found between IGF-1 and all-cause mortality. CONCLUSIONS: Higher IGFBP-1 and IGFBP-2 are associated with lower adiposity and decreased glucose tolearance but also with greater all-cause mortality. Higher levels of serum IGF-1 binding protein (IGFBP) may indicate greater IGF-1 activity and thus represent an association between higher IGF-1 activity and mortality in humans. |
| Keywords: | aging IGF-1 IGFBP mortality |